Alzheimer disease research in the 21st century: Past and current failures, new perspectives and funding priorities

Francesca Pistollato, Elan L. Ohayon, Ann Lam, Gillian R. Langley, Thomas J. Novak, David Pamies, George Perry, Eugenia D Trushina, Robin S B Williams, Alex E. Roher, Thomas Hartung, Stevan Harnad, Neal Barnard, Martha Clare Morris, Mei Chun Lai, Ryan Merkley, P. Charukeshi Chandrasekera

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Much of Alzheimer disease (AD) research has been traditionally based on the use of animals, which have been extensively applied in an effort to both improve our understanding of the pathophysiological mechanisms of the disease and to test novel therapeutic approaches. However, decades of such research have not effectively translated into substantial therapeutic success for human patients. Here we critically discuss these issues in order to determine how existing human-based methods can be applied to study AD pathology and develop novel therapeutics. These methods, which include patient-derived cells, computational analysis and models, together with large-scale epidemiological studies represent novel and exciting tools to enhance and forward AD research. In particular, these methods are helping advance AD research by contributing multifactorial and multidimensional perspectives, especially considering the crucial role played by lifestyle risk factors in the determination of AD risk. In addition to research techniques, we also consider related pitfalls and flaws in the current research funding system. Conversely, we identify encouraging new trends in research and government policy. In light of these new research directions, we provide recommendations regarding prioritization of research funding. The goal of this document is to stimulate scientific and public discussion on the need to explore new avenues in AD research, considering outcome and ethics as core principles to reliably judge traditional research efforts and eventually undertake new research strategies.

Original languageEnglish (US)
Pages (from-to)38999-39016
Number of pages18
JournalOncotarget
Volume7
Issue number26
StatePublished - 2016

Fingerprint

Alzheimer Disease
Research
Ethics
Life Style
Epidemiologic Studies
Research Design
Therapeutics
Outcome Assessment (Health Care)
Pathology

Keywords

  • Alzheimer disease
  • Animal models
  • Computational models
  • Gerotarget
  • Human methods
  • Induced pluripotent stem cells

ASJC Scopus subject areas

  • Oncology

Cite this

Pistollato, F., Ohayon, E. L., Lam, A., Langley, G. R., Novak, T. J., Pamies, D., ... Charukeshi Chandrasekera, P. (2016). Alzheimer disease research in the 21st century: Past and current failures, new perspectives and funding priorities. Oncotarget, 7(26), 38999-39016.

Alzheimer disease research in the 21st century : Past and current failures, new perspectives and funding priorities. / Pistollato, Francesca; Ohayon, Elan L.; Lam, Ann; Langley, Gillian R.; Novak, Thomas J.; Pamies, David; Perry, George; Trushina, Eugenia D; Williams, Robin S B; Roher, Alex E.; Hartung, Thomas; Harnad, Stevan; Barnard, Neal; Morris, Martha Clare; Lai, Mei Chun; Merkley, Ryan; Charukeshi Chandrasekera, P.

In: Oncotarget, Vol. 7, No. 26, 2016, p. 38999-39016.

Research output: Contribution to journalArticle

Pistollato, F, Ohayon, EL, Lam, A, Langley, GR, Novak, TJ, Pamies, D, Perry, G, Trushina, ED, Williams, RSB, Roher, AE, Hartung, T, Harnad, S, Barnard, N, Morris, MC, Lai, MC, Merkley, R & Charukeshi Chandrasekera, P 2016, 'Alzheimer disease research in the 21st century: Past and current failures, new perspectives and funding priorities', Oncotarget, vol. 7, no. 26, pp. 38999-39016.
Pistollato F, Ohayon EL, Lam A, Langley GR, Novak TJ, Pamies D et al. Alzheimer disease research in the 21st century: Past and current failures, new perspectives and funding priorities. Oncotarget. 2016;7(26):38999-39016.
Pistollato, Francesca ; Ohayon, Elan L. ; Lam, Ann ; Langley, Gillian R. ; Novak, Thomas J. ; Pamies, David ; Perry, George ; Trushina, Eugenia D ; Williams, Robin S B ; Roher, Alex E. ; Hartung, Thomas ; Harnad, Stevan ; Barnard, Neal ; Morris, Martha Clare ; Lai, Mei Chun ; Merkley, Ryan ; Charukeshi Chandrasekera, P. / Alzheimer disease research in the 21st century : Past and current failures, new perspectives and funding priorities. In: Oncotarget. 2016 ; Vol. 7, No. 26. pp. 38999-39016.
@article{28d9f5ac2b62419496fd4e385567fc2f,
title = "Alzheimer disease research in the 21st century: Past and current failures, new perspectives and funding priorities",
abstract = "Much of Alzheimer disease (AD) research has been traditionally based on the use of animals, which have been extensively applied in an effort to both improve our understanding of the pathophysiological mechanisms of the disease and to test novel therapeutic approaches. However, decades of such research have not effectively translated into substantial therapeutic success for human patients. Here we critically discuss these issues in order to determine how existing human-based methods can be applied to study AD pathology and develop novel therapeutics. These methods, which include patient-derived cells, computational analysis and models, together with large-scale epidemiological studies represent novel and exciting tools to enhance and forward AD research. In particular, these methods are helping advance AD research by contributing multifactorial and multidimensional perspectives, especially considering the crucial role played by lifestyle risk factors in the determination of AD risk. In addition to research techniques, we also consider related pitfalls and flaws in the current research funding system. Conversely, we identify encouraging new trends in research and government policy. In light of these new research directions, we provide recommendations regarding prioritization of research funding. The goal of this document is to stimulate scientific and public discussion on the need to explore new avenues in AD research, considering outcome and ethics as core principles to reliably judge traditional research efforts and eventually undertake new research strategies.",
keywords = "Alzheimer disease, Animal models, Computational models, Gerotarget, Human methods, Induced pluripotent stem cells",
author = "Francesca Pistollato and Ohayon, {Elan L.} and Ann Lam and Langley, {Gillian R.} and Novak, {Thomas J.} and David Pamies and George Perry and Trushina, {Eugenia D} and Williams, {Robin S B} and Roher, {Alex E.} and Thomas Hartung and Stevan Harnad and Neal Barnard and Morris, {Martha Clare} and Lai, {Mei Chun} and Ryan Merkley and {Charukeshi Chandrasekera}, P.",
year = "2016",
language = "English (US)",
volume = "7",
pages = "38999--39016",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "26",

}

TY - JOUR

T1 - Alzheimer disease research in the 21st century

T2 - Past and current failures, new perspectives and funding priorities

AU - Pistollato, Francesca

AU - Ohayon, Elan L.

AU - Lam, Ann

AU - Langley, Gillian R.

AU - Novak, Thomas J.

AU - Pamies, David

AU - Perry, George

AU - Trushina, Eugenia D

AU - Williams, Robin S B

AU - Roher, Alex E.

AU - Hartung, Thomas

AU - Harnad, Stevan

AU - Barnard, Neal

AU - Morris, Martha Clare

AU - Lai, Mei Chun

AU - Merkley, Ryan

AU - Charukeshi Chandrasekera, P.

PY - 2016

Y1 - 2016

N2 - Much of Alzheimer disease (AD) research has been traditionally based on the use of animals, which have been extensively applied in an effort to both improve our understanding of the pathophysiological mechanisms of the disease and to test novel therapeutic approaches. However, decades of such research have not effectively translated into substantial therapeutic success for human patients. Here we critically discuss these issues in order to determine how existing human-based methods can be applied to study AD pathology and develop novel therapeutics. These methods, which include patient-derived cells, computational analysis and models, together with large-scale epidemiological studies represent novel and exciting tools to enhance and forward AD research. In particular, these methods are helping advance AD research by contributing multifactorial and multidimensional perspectives, especially considering the crucial role played by lifestyle risk factors in the determination of AD risk. In addition to research techniques, we also consider related pitfalls and flaws in the current research funding system. Conversely, we identify encouraging new trends in research and government policy. In light of these new research directions, we provide recommendations regarding prioritization of research funding. The goal of this document is to stimulate scientific and public discussion on the need to explore new avenues in AD research, considering outcome and ethics as core principles to reliably judge traditional research efforts and eventually undertake new research strategies.

AB - Much of Alzheimer disease (AD) research has been traditionally based on the use of animals, which have been extensively applied in an effort to both improve our understanding of the pathophysiological mechanisms of the disease and to test novel therapeutic approaches. However, decades of such research have not effectively translated into substantial therapeutic success for human patients. Here we critically discuss these issues in order to determine how existing human-based methods can be applied to study AD pathology and develop novel therapeutics. These methods, which include patient-derived cells, computational analysis and models, together with large-scale epidemiological studies represent novel and exciting tools to enhance and forward AD research. In particular, these methods are helping advance AD research by contributing multifactorial and multidimensional perspectives, especially considering the crucial role played by lifestyle risk factors in the determination of AD risk. In addition to research techniques, we also consider related pitfalls and flaws in the current research funding system. Conversely, we identify encouraging new trends in research and government policy. In light of these new research directions, we provide recommendations regarding prioritization of research funding. The goal of this document is to stimulate scientific and public discussion on the need to explore new avenues in AD research, considering outcome and ethics as core principles to reliably judge traditional research efforts and eventually undertake new research strategies.

KW - Alzheimer disease

KW - Animal models

KW - Computational models

KW - Gerotarget

KW - Human methods

KW - Induced pluripotent stem cells

UR - http://www.scopus.com/inward/record.url?scp=84982924447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982924447&partnerID=8YFLogxK

M3 - Article

C2 - 27229915

AN - SCOPUS:84982924447

VL - 7

SP - 38999

EP - 39016

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 26

ER -